Journal of Gynecologic Oncology 2023

3 papers
The 2023 edition of the Journal of Gynecologic Oncology focused on refining surgical protocols and enhancing predictive modeling for gynecologic malignancies. Research themes emphasized the validation of alternative interventions through non-inferiority and equivalence testing, particularly regarding lymphadenectomy. Notable work included the LOVE study on early-stage ovarian cancer and the CQGOG0103 trial protocol, which evaluates lymph node dissection in stage IIICr cervical cancer prior to concurrent chemoradiotherapy. These studies address the generalizability gap in clinical research and the validity risks associated with open-label trials. Another central theme involved predictive risk stratification for organ-sparing surgery. Investigations into preoperative data, such as the role of PTEN mutations in predicting outcomes for fertility-preserving treatments in endometrial cancer, illustrated a move toward personalized care. Methodological contributions explored clinical predictive modeling using retrospective patient data and multi-pathway synergy in integrative adjunctive pharmacotherapy. Prolific authors contributing to these areas included Dongling Zou, Qing Liu, and Chao Wang. This year's research collectively sought to improve postoperative pathology predictions and optimize treatment outcomes through data-driven risk assessment.

Top Research Directions

The 7 research directions with Journal of Gynecologic Oncology 2023 papers, ranked by paper count. Share is the fraction of the edition’s papers in the direction.

#DirectionPapersShare
1Preoperative Staging Inaccuracy and Stage Migration266.7%
2Designing Non-Inferiority Clinical Trials133.3%
3Integrated Histomolecular Stratification for Cancer Prognosis133.3%
4Open-Label Bias in Clinical Trials133.3%
5Quantifying Biological Heterogeneity Beyond Anatomical Staging133.3%
6Stratified Randomization for Balanced Experimental Arms133.3%
7The Oncological Mechanics of En Bloc Resection133.3%

Download all directions as CSV

Institutions

Institutions credited by Journal of Gynecologic Oncology 2023 papers: a paper credits every institution named in its affiliations, once. 26 institutions share 3 credited papers.

#InstitutionPapersShare
1Fudan University 3100.0%
2Chongqing University 266.7%
300raa0r66 133.3%
401413r497 133.3%
50144s0951 133.3%
601k1x3b35 133.3%
701mdjbm03 133.3%
804dn2ax39 133.3%
904xy45965 133.3%
1005d5vvz89 133.3%
1105jb9pq57 133.3%
12Chinese Academy of Sciences 133.3%
13Fujian Medical University 133.3%
14Guangzhou Medical University 133.3%
15Huazhong University of Science and Technology 133.3%
16Jinan University 133.3%
17Obstetrics and Gynecology Hospital of Fudan University 133.3%
18Peking University Third Hospital 133.3%
19Shanghai Jiao Tong University 133.3%
20Shantou University 133.3%
21Sina (China) 133.3%
22Sun Yat-sen University Cancer Center 133.3%
23Tongji University 133.3%
24University of Chinese Academy of Sciences 133.3%
25University of Hong Kong 133.3%
26Zhejiang University 133.3%

Download all institutions as CSV

About this data

Papers. Journal of Gynecologic Oncology 2023 lists 3 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 3 of 3 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Gynecologic Oncology 2023”, https://lacuna.tiptreesystems.com/venue/journal-of-gynecologic-oncology/2023.

Papers

Title
A prospective randomized multicenter trial for lymphadenectomy in early-stage ovarian cancer: LOVE study
Efficacy of lymph node dissection on stage IIICr of cervical cancer before CCRT: study protocol for a phase III, randomized controlled clinical trial (CQGOG0103)
PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia